Recent Updates
Recently added Catalysts

LY4329090

Phase 1

Obesity | Small molecule | Metabolic |Eli Lilly and Company|Last Updated: Sep 8, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment184

FDA Designations

No designations recorded

Clinical trial landscape

LY4329090 · 1 trial · 2 indications

Phase 1 1
NCT07808073A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise HealthyObesity
NOT YET_RECRUITING184 Analytics
PHASE1NOT YET_RECRUITING
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Obesity
NCT07808073184
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
End of Study (Week 28)

Secondary Endpoints

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4329090
Baseline through Week 28
PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4329090
Baseline through Week 28
PK: Area Under the Concentration Versus Time Curve (AUC) of LY4329090
Baseline through Week 28
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
LY4329090 Part AEXPERIMENTALParticipants will receive LY4329090 administered subcutaneously (SC)
Placebo Part AEXPERIMENTALParticipants will receive placebo administered SC
LY4329090 Part BEXPERIMENTALParticipants will receive LY4329090 administered SC
Placebo Part BPLACEBO_COMPARATORParticipants will receive placebo administered SC

Interventions

NameTypeDescription
LY4329090DRUGAdministered SC
PlaceboDRUGAdministered SC
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: * Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent. * Are overtly healthy with no comorbidities related to body mass index (BMI). * Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m²,...

Countries:United StatesSingapore
Unlock Eligibility Criteria

Competitive Landscape -Obesity 185 trials

Top 20 of 32 competitors

CompanyTickerTrialsLead PhaseDrugs
Amgen Inc.AMGN8PHASE3Maridebart cafraglutide
Eli Lilly and CompanyLLY37PHASE3Orforglipron
Novo Nordisk A/S Sponsored ADR Class BNVO45PHASE3Cagrilintide, Semaglutide
Rhythm Pharmaceuticals, Inc.RYTM6PHASE3Setmelanotide
Regeneron Pharmaceuticals, Inc.REGN3PHASE3Mibavademab
Pfizer Inc.PFE1PHASE3PF-08653944
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
Kailera Therapeutics, Inc.KLRA4PHASE3Ribupatide
AstraZeneca PLCAZN3PHASE2AZD6234
PfizerMTSR3PHASE3MET097
Structure Therapeutics, Inc. Sponsored ADRGPCR2PHASE2Undisclosed
Biohaven Ltd.BHVN1PHASE2Taldefgrobep Alfa
Skye Bioscience, Inc.SKYE1PHASE2Nimacimab, semaglutide
Palatin Technologies, Inc.PTN1PHASE2bremelanotide, tirzepatide
Veru IncVERU1PHASE2Enobosarm, Semaglutide weekly
Arrowhead Pharmaceuticals, Inc.ARWR2PHASE1ARO-INHBE, Tirzepatide
Alnylam Pharmaceuticals, IncALNY1PHASE1ALN-2232, Tirzepatide
Gilead Sciences, Inc.GILD1PHASE1GS-4571, Omeprazole
AbbVie, Inc.ABBV1PHASE1ABBV-295
MBX Biosciences, Inc.MBX1PHASE1MBX 4291
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWSep 8, 2026NCT07808073NEW_TRIAL: changed
LOWSep 8, 2026NCT07808073NEW_TRIAL: changed